IVAX Diagnostics Appoints New Board Members to Fill Vacancies

Business Wire, April 20, 2006

MIAMI -- IVAX Diagnostics, Inc. (AMEX:IVD) announced today that Dr. Phillip Frost, Neil Flanzraich, and Dr. Jane Hsiao resigned from IVAX Diagnostics, Inc.'s Board of Directors (the "Board"), and Dr. Itzhak Krinsky, Mark Durand and Richard Egosi were appointed to the Board to fill the vacancies and to serve until the next annual meeting of stockholders.

Dr. Krinsky, who is the Corporate Vice President - Business Development of Teva Pharmaceutical Industries Limited, has succeeded Dr. Frost as the non-executive Chairman of the Board. Mr. Durand is the Chief Financial Officer and Senior Vice President - Finance and Business Development for Teva North America. Mr. Egosi is the Senior Vice President and General Counsel for Teva North America.

Dr. Krinsky said, "We thank Dr. Frost, Mr. Flanzraich and Dr. Hsiao for their valuable service on the board of IVAX Diagnostics. As Teva continues the process of integrating the IVAX business units, we look forward to working with the management of IVAX Diagnostics to leverage the company's strengths and capitalize on new opportunities."

About IVAX Diagnostics, Inc.

IVAX Diagnostics, Inc., headquartered in Miami, Florida, develops, manufactures and markets proprietary diagnostic reagents, instrumentation, and software in the United States and Italy through its three subsidiaries: Diamedix Corporation, Delta Biologicals S.r.l., and ImmunoVision, Inc. Teva Pharmaceutical Industries Limited, through its wholly-owned IVAX Corporation subsidiary, owns approximately 72% of IVAX Diagnostics, Inc.

Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect the business and prospects of IVAX Diagnostics, Inc., including, without limitation, risks and uncertainties that: the IVAX business units, including, without limitation, IVAX Diagnostics, may not be successfully integrated by Teva Pharmaceutical Industries Limited ("Teva"); IVAX Diagnostics' strengths may not be able to be successfully leveraged and IVAX Diagnostics may not be able to capitalize on new opportunities, including, without limitation, with respect to the PARSEC(TM) System, hepatitis product technology, and strategic acquisitions and alliances; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in IVAX Diagnostics' filings with the Securities and Exchange Commission.